536 related articles for article (PubMed ID: 16077073)
1. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment.
Urosevic M; Dummer R; Conrad C; Beyeler M; Laine E; Burg G; Gilliet M
J Natl Cancer Inst; 2005 Aug; 97(15):1143-53. PubMed ID: 16077073
[TBL] [Abstract][Full Text] [Related]
2. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.
Wenzel J; Uerlich M; Haller O; Bieber T; Tueting T
J Cutan Pathol; 2005 Apr; 32(4):257-62. PubMed ID: 15769273
[TBL] [Abstract][Full Text] [Related]
3. [New perspective in immunotherapy: local imiquimod treatment].
Kemény L; Nagy N
Orv Hetil; 2010 May; 151(19):774-83. PubMed ID: 20427260
[TBL] [Abstract][Full Text] [Related]
4. Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-alpha?
Urosevic M; Oberholzer PA; Maier T; Hafner J; Laine E; Slade H; Benninghoff B; Burg G; Dummer R
Clin Cancer Res; 2004 Aug; 10(15):4959-70. PubMed ID: 15297396
[TBL] [Abstract][Full Text] [Related]
5. Viral and nonviral uses of imiquimod: a review.
Gupta AK; Cherman AM; Tyring SK
J Cutan Med Surg; 2004; 8(5):338-52. PubMed ID: 15868314
[TBL] [Abstract][Full Text] [Related]
6. Imiquimod 5% cream in the treatment of Bowen's disease and invasive squamous cell carcinoma.
Peris K; Micantonio T; Fargnoli MC; Lozzi GP; Chimenti S
J Am Acad Dermatol; 2006 Aug; 55(2):324-7. PubMed ID: 16844522
[TBL] [Abstract][Full Text] [Related]
7. Imiquimod for superficial and in situ skin malignancy.
Drug Ther Bull; 2009 Oct; 47(10):113-6. PubMed ID: 19809085
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of genital Bowen's disease with imiquimod 5% cream.
Kishi C; Shimizu A; Kato M; Amano H; Ishikawa O
Int J STD AIDS; 2015 Sep; 26(10):752-4. PubMed ID: 25258393
[TBL] [Abstract][Full Text] [Related]
9. Imiquimod in basal cell carcinoma: how does it work?
Dummer R; Urosevic M; Kempf W; Hoek K; Hafner J; Burg G
Br J Dermatol; 2003 Nov; 149 Suppl 66():57-8. PubMed ID: 14616353
[TBL] [Abstract][Full Text] [Related]
10. Topical imiquimod 5% cream in the treatment of Bowen's disease of the penis.
Cook-Bolden F; Weinberg JM
J Am Acad Dermatol; 2002 Jan; 46(1):146-7. PubMed ID: 11756968
[No Abstract] [Full Text] [Related]
11. Treatment of Bowen's disease with topical 5% imiquimod cream: retrospective study.
Rosen T; Harting M; Gibson M
Dermatol Surg; 2007 Apr; 33(4):427-31; discussion 431-2. PubMed ID: 17430376
[TBL] [Abstract][Full Text] [Related]
12. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells.
Drobits B; Holcmann M; Amberg N; Swiecki M; Grundtner R; Hammer M; Colonna M; Sibilia M
J Clin Invest; 2012 Feb; 122(2):575-85. PubMed ID: 22251703
[TBL] [Abstract][Full Text] [Related]
13. A cost analysis of photodynamic therapy with methyl aminolevulinate and imiquimod compared with conventional surgery for the treatment of superficial basal cell carcinoma and Bowen's disease of the lower extremities.
Aguilar M; de Troya M; Martin L; Benítez N; González M
J Eur Acad Dermatol Venereol; 2010 Dec; 24(12):1431-6. PubMed ID: 20456549
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of Bowen's disease of the penis with imiquimod 5% cream].
de Diego Rodríguez E; Villanueva Peña A; Hernández Castrillo A; Gómez Ortega JM
Actas Urol Esp; 2005 Sep; 29(8):797-800. PubMed ID: 16304915
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo.
Urosevic M; Maier T; Benninghoff B; Slade H; Burg G; Dummer R
Arch Dermatol; 2003 Oct; 139(10):1325-32. PubMed ID: 14568837
[TBL] [Abstract][Full Text] [Related]
16. Imiquimod for the treatment of Bowen's disease and invasive squamous cell carcinoma.
Nouri K; O'Connell C; Rivas MP
J Drugs Dermatol; 2003 Dec; 2(6):669-73. PubMed ID: 14711149
[TBL] [Abstract][Full Text] [Related]
17. Nature of inflammatory infiltrate in superficial cutaneous malignancies during topical imiquimod treatment.
Wolf IH; Kodama K; Cerroni L; Kerl H
Am J Dermatopathol; 2007 Jun; 29(3):237-41. PubMed ID: 17519620
[TBL] [Abstract][Full Text] [Related]
18. [Photodynamic therapy vs imiquimod].
Serra-Guillén C; Nagore E; Guillén C
Actas Dermosifiliogr; 2012; 103(6):488-501. PubMed ID: 22178262
[TBL] [Abstract][Full Text] [Related]
19. Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis.
Majewski S; Marczak M; Mlynarczyk B; Benninghoff B; Jablonska S
Int J Dermatol; 2005 Jan; 44(1):14-9. PubMed ID: 15663652
[TBL] [Abstract][Full Text] [Related]
20. [Spindle-cell carcinoma in situ treated with 5% imiquimod].
Martínez S; del Boz J; Vera A; Sanz A; Crespo V
Actas Dermosifiliogr; 2006 May; 97(4):267-70. PubMed ID: 16801022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
